Founder of Biocon, India's largest listed biopharma firm and maker of drugs for diseases such as cancer and diabetes, aims to more than double its revenues to $1 billion by 2018. Ahead of a long-awaited listing of research services arm, Syngene, Biocon bought back GE Capital's 7.7 percent stake in it for $35 million, and sold 10 percent to investment firm Silver Leaf Oak.
Fast Fact: She was awarded the Global Economy Prize by Germany's Kiel Institute, in June.